Sectors

ICLR
ICON Public Limited Company
159.66
1 x 114.02
1 x 189.28
bid
ask
+
16.99
11.91%
01:35 PM
timesize
Ytd -12.38%
1y 7.49%
147.71
day range
160.88
66.57
52 week range
211.00
Open 147.79 Prev Close 142.67 Low 147.71 High 160.88 Mkt Cap 12.22B
Vol 1.18M Avg Vol 1.14M EPS 2.28 P/E 70.00 Forward P/E 12.03
Beta 1.27 Short Ratio 2.45 Inst. Own 108.98% Dividend N/A Div Yield N/A
Ex Div Date N/A Earning 07-23 50-d Avg 125.89 200-d Avg 149.35 1yr Est 154.19
Earning
Date For Estimate Reported Surprise surprise %
2026-05-13 2026-03 2.95 N/A N/A N/A
2026-04-01 2025-12 3.3 N/A N/A N/A
2025-10-22 2025-09 3.28 3.31 0.03 0.91%
2025-07-23 2025-06 3.18 3.26 0.08 2.52%
2025-04-30 2025-03 3.08 3.19 0.11 3.57%
2025-02-19 2024-12 3.42 3.43 0.01 0.29%
Upgrade / Downgrade
Date Firm Action From To
2026-06-01 TD Cowen Upgrade Buy Buy
2026-06-01 B of A Securities Upgrade Underperform Underperform
2026-05-29 Citigroup Upgrade Neutral Neutral
2026-05-29 Truist Securities Upgrade Hold Hold
2026-05-29 RBC Capital Upgrade Sector Perform Sector Perform
2026-05-29 JP Morgan Upgrade Neutral Neutral
Profile
ICON Public Limited Company, a clinical research organization, provides outsourced development and commercialization services in Ireland, rest of Europe, the United States, and internationally. The company specializes in the strategic development, management, and analysis of programs that support various stages of the clinical development process from compound selection to Phase I-IV clinical studies. It also provides clinical development services, including all phases of development, peri and post approval, data solutions, and site and patient access services; clinical trial management, consulting, and contract staffing services; and commercial services comprising clinical development strategy, planning and trial design, full study execution, and post-market commercialization. In addition, the company offers laboratory services, including bionanalytical, biomarker, vaccine, good manufacturing practice, and central laboratory services, as well as full-service and functional service partnerships to customers. Further, the company provides adaptive trials, cardiac safety solutions, clinical and scientific operations, consulting and advisory, commercial positioning, decentralized and hybrid clinical trials, early clinical, laboratories, language services, medical imaging, real world intelligence, site and patient, and strategic solutions. It serves pharmaceutical, biotechnology, and medical device industries, as well as government and public health organizations. The company has a strategic alliance with Advarra, Inc. for the development of a connected, research-ready clinical trial site network model. ICON Public Limited Company was incorporated in 1989 and is headquartered in Dublin, Ireland.
Institution Ownership
Report Date Organization Position Value Percentage
2026-03-30 Artisan Partners Limited Partnership 8.28M 1.18B 10.84%
2026-03-30 Wellington Management Group, LLP 5.91M 843.61M 7.74%
2026-03-30 Harris Associates L.P. 4.35M 620.80M 5.70%
2026-03-30 FMR, LLC 4.17M 595.51M 5.47%
2026-03-30 Invesco Ltd. 3.88M 553.40M 5.08%
2026-03-30 Principal Financial Group, Inc. 3.31M 472.49M 4.34%
Fund Ownership
Report Date Organization Position Value Percentage
2026-03-30 Artisan Partners Funds Inc.-Artisan International Value Fund 6.32M 902.12M 8.28%
2026-03-30 HARRIS ASSOCIATES INVESTMENT TRUST-Oakmark Select Fund 2.26M 321.86M 2.95%
2026-01-30 VANGUARD SPECIALIZED FUNDS-Vanguard Health Care Fund 1.21M 173.19M 1.59%
2026-01-30 VANGUARD WINDSOR FUNDS-Vanguard Windsor Fund 999.22K 142.56M 1.31%
2026-01-30 AIM Sector Funds (Invesco Sector Funds)-INVESCO SMALL CAP VALUE FUND 975.20K 139.13M 1.28%
2026-01-30 Principal Funds, Inc-International Equity Fund 971.39K 138.59M 1.27%
Split
Split Date
2 : 1 2008-08-13
2 : 1 2006-10-24